Silencing disease genes in the laboratory and the clinic

Journal of Pathology

Volumn 226, Issue 2, 2012, Pages 365-379

  Watts, Jonathan K ^a   Corey, David R ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

antisense oligonucleotides; gene silencing; mRNA; siRNA; therapeutics

Indexed keywords

AEG 35156; AGANIRSEN; ALICAFORSEN; ALN RSV 01; ANTISENSE OLIGONUCLEOTIDE; ASM8; CUSTIRSEN; DOUBLE STRANDED RNA; DYSTROPHIN; ETEPLIRSEN; EXCELLAIR; GATAPARSEN; GSK 2402968; IMETELSTAT; IMO 2055; LOCKED NUCLEIC ACID; LOR 2040; MESSENGER RNA; MIPOMERSEN; MIRAVIRSEN; MOLECULAR THERAPY AGENT; OGX 427; PF 655; PHOSPHOROTHIOIC ACID; PRO 044; PRO044; QPI 1002; RNA INDUCED SILENCING COMPLEX; SMALL INTERFERING RNA; TRABEDERSEN; UNCLASSIFIED DRUG;

ASTHMA; BRAIN CANCER; BREAST CANCER; CELL TRANSPORT; CHEMICAL MODIFICATION; CORNEA NEOVASCULARIZATION; DIABETIC MACULAR EDEMA; DNA SYNTHESIS; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; EXON; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOGENICITY; INTRON; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MOLECULARLY TARGETED THERAPY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RNA CLEAVAGE; RNA INTERFERENCE; RNA SPLICING; RNA SYNTHESIS; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ALTERNATIVE SPLICING; CELLS, CULTURED; CLINICAL TRIALS AS TOPIC; GENE SILENCING; GENE THERAPY; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; RESEARCH DESIGN; RNA, SMALL INTERFERING;

EID: 82755161958     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2993     Document Type: Review

References (187)

1. Stephenson ML, Zamecnik PC,. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 1978; 75: 285-288. (Pubitemid 8290784)
2. Zamecnik PC, Stephenson ML,. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-284. (Pubitemid 8290783)
3. Agrawal S, Remembering Paul C,. Zamecnik, M.D., 'Father of antisense' (1912-2009). Oligonucleotides 2010; 20: 47-50.
4. Eckstein F,. Developments in RNA chemistry, a personal view. Biochimie 2002; 84: 841-848. (Pubitemid 35422910)
5. Geary RS, Yu RZ, Levin AA,. Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Invest Drugs 2001; 2: 562-573. (Pubitemid 32401151)
6. Watanabe TA, Geary RS, Levin AA,. Plasma protein binding of an antisense oligonucleotide targeting human ICAM-1 (ISIS 2302). Oligonucleotides 2006; 16: 169-180.
7. Stein CA, Krieg AM,. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev 1994; 4: 67-69. (Pubitemid 24308373)
8. Thiel KW, Giangrande PH,. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 2009; 19: 209-222.
9. Chiang MY, Chan H, Zounes MA, et al., Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J Biol Chem 1991; 266: 18162-18171. (Pubitemid 21908061)
10. Williams DM, Benseler F, Eckstein F,. Properties of 2′- fluorothymidine-containing oligonucleotides: interaction with restriction endonuclease EcoRV. Biochemistry 1991; 30: 4001-4009.
11. Pieken WA, Olsen DB, Aurup H, et al., Structure-function relationship of hammerhead ribozymes as probed by 2′-modifications. Nucleic Acids Symp Ser 1991; 24: 51-53.
12. Kawasaki AM, Casper MD, Freier SM, et al., Uniformly modified 2′-deoxy-2′-fluoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 1993; 36: 831-841. (Pubitemid 23118776)
13. Monia BP, Lesnik EA, Gonzalez C, et al., Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514-14522. (Pubitemid 23195583)
14. Freier SM, Altmann K-H,. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA: RNA duplexes. Nucleic Acids Res 1997; 25: 4429-4443. (Pubitemid 27500751)
15. Martin P,. A new access to 2′-O-alkylated ribonucleosides and properties of 2′-O-alkylated oligoribonucleotides. Helv Chim Acta 1995; 78: 486-504.
16. Koshkin AA, Singh SK, Nielsen P, et al., LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998; 54: 3607-3630. (Pubitemid 28108183)
17. Obika S, Nanbu D, Hari Y, et al., Stability and structural features of the duplexes containing nucleoside analogues with a fixed N-type conformation, 2′-O,4′-C-methyleneribonucleosides. Tetrahedron Lett 1998; 39: 5401-5404. (Pubitemid 28295121)
18. Braasch DA, Corey DR,. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Biol 2001; 8: 1-7. (Pubitemid 32165807)
19. Leumann CJ,. DNA analogues: from supramolecular principles to biological properties. Bioorg Med Chem 2002; 10: 841-854. (Pubitemid 34139898)
20. Obika S,. Development of bridged nucleic acid analogues for antigene technology. Chem Pharm Bull (Tokyo) 2004; 52: 1399-1404. (Pubitemid 41364414)
21. Christensen NK, Petersen M, Nielsen P, et al., A novel class of oligonucleotide analogues containing 2′-O,3′-C-linked [3.2.0]bicycloarabinonucleoside monomers: synthesis, thermal affinity studies, and molecular modeling. J Am Chem Soc 1998; 120: 5458-5463.
22. Rajwanshi VK, Hakansson AE, Sorensen MD, et al., The eight stereoisomers of LNA (locked nucleic acid): a remarkable family of strong RNA binding molecules. Angew Chem Int Ed Engl 2000; 39: 1656-1659. (Pubitemid 30304102)
23. Morita K, Hasegawa C, Kaneko M, et al., 2′-O,4′-C-ethylene- bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg Med Chem Lett 2002; 12: 73-76. (Pubitemid 34008572)
24. Renneberg D, Bouliong E, Reber U, et al., Antisense properties of tricyclo-DNA. Nucleic Acids Res 2002; 30: 2751-2757. (Pubitemid 34778133)
25. Hari Y, Obika, S, Ohnishi R, et al., Synthesis and properties of 2′-O,4′-C-methyleneoxymethylene bridged nucleic acid. Bioorg Med Chem 2006; 14: 1029-1038. (Pubitemid 43059794)
26. Srivastava P, Barman J, Pathmasiri W, et al., Five- and six-membered conformationally locked 2′,4′-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies. J Am Chem Soc 2007; 129: 8362-8379. (Pubitemid 47035147)
27. Bramsen JB, Laursen MB, Nielsen AF, et al., A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009; 37: 2867-2881.
28. Straarup EM, Fisker N, Hedtjarn M, et al., Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 2010; 38: 7100-7111.
29. Wu H, Lima WF, Zhang H, et al., Determination of the role of the human RNase H1 in the pharmacology of DNA-like antisense drugs. J Biol Chem 2004; 279: 17181-17189. (Pubitemid 38560475)
30. Minshull J, Hunt T,. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res 1986; 14: 6433-6451.
31. Nakamura H, Oda Y, Iwai S, et al., How does RNase H recognize a DNA.RNA hybrid? Proc Natl Acad Sci U S A 1991; 88: 11535-11539. (Pubitemid 21916076)
32. Wahlestedt C, Salmi P, Good L, et al., Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc Natl Acad Sci U S A 2000; 97: 5633-5638. (Pubitemid 30313770)
33. Damha MJ, Wilds CJ, Noronha A, et al., Hybrids of RNA and arabinonucleic acids (ANA and 2′F-ANA) are substrates of ribonuclease H. J Am Chem Soc 1998; 120: 12976-12977. (Pubitemid 29013857)
34. Watts JK, Damha MJ,. 2′F-Arabinonucleic acids (2′F-ANA)- history, properties, and new frontiers. Can J Chem 2008; 86: 641-656.
35. Nielsen PE, Egholm M, Berg RH, et al., Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 1991; 254: 1497-1500. (Pubitemid 21917487)
36. Bentin T, Nielsen PE,. Enhanced peptide nucleic acid binding to supercoiled DNA: possible implications for DNA 'breathing' dynamics. Biochemistry 1996; 35: 8863-8869. (Pubitemid 26243727)
37. Smulevitch SV, Simmons CG, Norton JC, et al., Enhancement of strand invasion by oligonucleotides through manipulation of backbone charge. Nature Biotechnol 1996; 14: 1700-1704. (Pubitemid 26414815)
38. Summerton J, Weller D,. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev 1997; 7: 187-195. (Pubitemid 27323077)
39. Corey DR, Abrams JM,. Morpholino antisense oligonucleotides: tools for investigating vertebrate development. Genome Biol 2001; 2: reviews1015.1- reviews1015.3.
40. Bill BR, Petzold AM, Clark KJ, et al., A primer for morpholino use in zebrafish. Zebrafish 2009; 6: 69-77.
41. Pan Q, Shai O, Lee LJ, et al., Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genet 2008; 40: 1413-1415.
42. Aartsma-Rus A, van Ommen GJ,. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007; 13: 1609-1624. (Pubitemid 47481669)
43. Bauman J, Jearawiriyapaisarn N, Kole R,. Therapeutic potential of splice-switching oligonucleotides. Oligonucleotides 2009; 19: 1-13.
44. Dominski Z, Kole R,. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci U S A 1993; 90: 8673-8677. (Pubitemid 23277732)
45. Hua Y, Sahashi K, Hung G, et al., Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010; 24: 1634-1644.
46. Goemans NM, Tulinius M, van den Akker JT, et al., Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513-1522.
47. Aartsma-Rus A, van Ommen GJ,. Less is more: therapeutic exon skipping for Duchenne muscular dystrophy. Lancet Neurol 2009; 8: 873-875.
48. Alter J, Lou F, Rabinowitz A, et al., Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nature Med 2006; 12: 175-177. (Pubitemid 43214742)
49. Suwanmanee T, Sierakowska H, Fucharoen S, et al., Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol Ther 2002; 6: 718-726. (Pubitemid 36054305)
50. Suwanmanee T, Sierakowska H, Lacerra G, et al., Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol Pharmacol 2002; 62: 545-553. (Pubitemid 36329373)
51. Wan J, Sazani P, Kole R,. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 2009; 124: 772-777.
52. Bauman JA, Li SD, Yang A, et al., Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Res 2010; 38: 8348-8356.
53. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
54. Farazi TA, Spitzer JI, Morozov P, et al., miRNAs in human cancer. J Pathol 2011; 223: 102-115.
55. Garzon R, Marcucci G, Croce CM,. Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Rev Drug Discov 2010; 9: 775-789.
56. Soifer HS, Rossi JJ, Saetrom P,. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007; 15: 2070-2079. (Pubitemid 350148921)
57. Lu M, Zhang Q, Deng M, et al., An analysis of human microRNA and disease associations. PLoS One 2008; 3: e3420.
58. Jiang Q, Wang Y, Hao Y, et al., miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009; 37: D98-D104.
59. Esau CC,. Inhibition of microRNA with antisense oligonucleotides. Methods 2008; 44: 55-60. (Pubitemid 350297990)
60. Davis S, Propp S, Freier SM, et al., Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 2009; 37: 70-77.
61. Montgomery RL, van Rooij E,. Therapeutic advances in microRNA targeting. J Cardiovasc Pharmacol 2011; 57: 1-7.
62. Girard M, Jacquemin E, Munnich A, et al., miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48: 648-656.
63. Krutzfeldt J, Rajewsky N, Braich R, et al., Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689.
64. Esau C, Davis S, Murray SF, et al., miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87-98.
65. Elmen J, Lindow M, Schutz S, et al., LNA-mediated microRNA silencing in non-human primates. Nature 2008; 452: 896-899. (Pubitemid 351550859)
66. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al., Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327: 198-201.
67. Fabani MM, Gait MJ,. miR-122 targeting with LNA/2′-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008; 14: 336-346. (Pubitemid 351171593)
68. Orom UA, Kauppinen S, Lund AH,. LNA-modified oligonucleotides mediate specific inhibition of microRNA function. Gene 2006; 372: 137-141.
69. Meister G, Landthaler M, Dorsett Y, et al., Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA 2004; 10: 544-550. (Pubitemid 38241013)
70. Kloosterman WP, Lagendijk AK, Ketting RF, et al., Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development. PLoS Biol 2007; 5: e203.
71. Siomi H, Siomi MC,. On the road to reading the RNA-interference code. Nature 2009; 457: 396-404.
72. Elbashir SM, Harborth J, Lendeckel W, et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498. (Pubitemid 32494397)
73. Watts JK, Deleavey GF, Damha MJ,. Chemically modified siRNA: tools and applications. Drug Discov Today 2008; 13: 842-855.
74. Morrissey DV, Lockridge JA, Shaw L, et al., Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nature Biotechnol 2005; 23: 1002-1007. (Pubitemid 41114035)
75. Morrissey DV, Blanchard K, Shaw L, et al., Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 2005; 41: 1349-1356. (Pubitemid 40770288)
76. Allerson CR, Sioufi N, Jarres R, et al., Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 2005; 48: 901-904. (Pubitemid 40270434)
77. Braasch DA, Paroo Z, Constantinescu A, et al., Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004; 14: 1139-1143. (Pubitemid 38229843)
78. Koller E, Propp S, Murray H, et al., Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 2006; 34: 4467-4476. (Pubitemid 44567046)
79. Deleavey GF, Watts JK, Alain T, et al., Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencing. Nucleic Acids Res 2010; 38: 4547-4557.
80. Marques JT, Williams BRG,. Activation of the mammalian immune system by siRNAs. Nature Biotechnol 2005; 23: 1399-1405. (Pubitemid 41679392)
81. Robbins M, Judge A, MacLachlan I,. siRNA and innate immunity. Oligonucleotides 2009; 19: 89-102.
82. Olejniczak M, Galka P, Krzyzosiak WJ,. Sequence-non-specific effects of RNA interference triggers and microRNA regulators. Nucleic Acids Res 2010; 38: 1-16.
83. Schlee M, Hornung V, Hartmann G,. siRNA and isRNA: two edges of one sword. Mol Ther 2006; 14: 463-470. (Pubitemid 44296098)
84. Poeck H, Besch R, Maihoefer C, et al., 5′-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nature Med 2008; 14: 1256-1263.
85. Kortylewski M, Swiderski P, Herrmann A, et al., In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotechnol 2009; 27: 925-932.
86. Gantier MP, Tong S, Behlke MA, et al., Rational design of immunostimulatory siRNAs. Mol Ther 2010; 18: 785-795.
87. Khairuddin N, Gantier MP, Blake SJ, et al., siRNA-induced immunostimulation through TLR7 promotes antitumoral activity against HPV-driven tumors in vivo. Immunol Cell Biol 2011; DOI: 10.1038/icb.2011.19.
88. Judge A, MacLachlan I,. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008; 19: 111-124. (Pubitemid 351271512)
89. Judge AD, Bola G, Lee ACH, et al., Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther 2006; 13: 494-505. (Pubitemid 43257617)
90. Corey DR,. Chemical modification: the key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-3622. (Pubitemid 350224067)
91. Watts JK, Corey DR,. Clinical status of duplex RNA. Bioorg Med Chem Lett 2010; 20: 3203-3207.
92. Kim D-H, Behlke MA, Rose SD, et al., Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nature Biotechnol 2005; 23: 222-226. (Pubitemid 40255333)
93. Collingwood MA, Rose SD, Huang L, et al., Chemical modification patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides 2008; 18: 187-200. (Pubitemid 352019751)
94. Yuan B, Latek R, Hossbach M, et al., siRNA Selection Server: an automated siRNA oligonucleotide prediction server. Nucleic Acids Res 2004; 32: W130-W134. (Pubitemid 38997314)
95. Boese Q, Leake D, Reynolds A, et al., Mechanistic insights aid computational short interfering RNA design. Methods Enzymol 2005; 392: 73-96. (Pubitemid 40092509)
96. Huesken D, Lange J, Mickanin C, et al., Design of a genome-wide siRNA library using an artificial neural network. Nature Biotechnol 2005; 23: 995-1001. (Pubitemid 41114034)
97. Sczakiel G, Homann M, Rittner K,. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res Dev 1993; 3: 45-52. (Pubitemid 23152124)
98. Stull RA, Taylor LA, Szoka FC Jr,. Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acids Res 1992; 20: 3501-3508.
99. Sczakiel G,. Theoretical and experimental approaches to design effective antisense oligonucleotides. Front Biosci 2000; 5: D194-D201.
100. Gifford LK, Opalinska JB, Jordan D, et al., Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching fluorescent reporter molecules. Nucleic Acids Res 2005; 33: e28.
101. Rittner K, Burmester C, Sczakiel G,. In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1. Nucleic Acids Res 1993; 21: 1381-1387. (Pubitemid 23154368)
102. Ho SP, Bao Y, Lesher T, et al., Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnol 1998; 16: 59-63. (Pubitemid 28035950)
103. Kronenwett R, Haas R, Sczakiel G,. Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J Mol Biol 1996; 259: 632-644. (Pubitemid 26226004)
104. Milner N, Mir KU, Southern EM,. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol 1997; 15: 537-541. (Pubitemid 27251570)
105. Rudnick SI, Swaminathan J, Sumaroka M, et al., Effects of local mRNA structure on posttranscriptional gene silencing. Proc Natl Acad Sci U S A 2008; 105: 13787-13792.
106. Bacon TA, Wickstrom E,. Walking along human c-myc mRNA with antisense oligodeoxynucleotides: maximum efficacy at the 5′ cap region. Oncogene Res 1991; 6: 13-19.
107. Stewart AJ, Canitrot Y, Baracchini E, et al., Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996; 51: 461-469. (Pubitemid 26072566)
108. [No authors listed]. Whither RNAi? Nature Cell Biol 2003; 5: 489-490.
109. Levin AA,. A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1999; 1489: 69-84.
110. Bunka DHJ, Stockley PG,. Aptamers come of age-at last. Nat Rev Microbiol 2006; 4: 588-596. (Pubitemid 44317021)
111. Robbins M, Judge A, Ambegia E, et al., Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008; 19: 991-999.
112. Kleinman ME, Yamada K, Takeda A, et al., Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008; 452: 591-597. (Pubitemid 351483358)
113. Yi R, Doehle BP, Qin Y, et al., Overexpression of exportin 5 enhances RNA interference mediated by short hairpin RNAs and microRNAs. RNA 2005; 11: 220-226. (Pubitemid 40165636)
114. Grimm D, Streetz KL, Jopling CL, et al., Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541. (Pubitemid 44050158)
115. Khan AA, Betel D, Miller ML, et al., Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nature Biotechnol 2009; 27: 549-555.
116. Jackson AL, Bartz SR, Schelter J, et al., Expression profiling reveals off-target gene regulation by RNAi. Nature Biotechnol 2003; 21: 635-637. (Pubitemid 36638089)
117. Fedorov Y, Anderson EM, Birmingham A, et al., Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 12: 1188-1196. (Pubitemid 43990544)
118. Jackson AL, Burchard J, Schelter J, et al., Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12: 1179-1187. (Pubitemid 43990543)
119. Jackson AL, Burchard J, Leake D, et al., Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 2006; 12: 1197-1205. (Pubitemid 43990545)
120. Bramsen JB, Laursen MB, Damgaard CK, et al., Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res 2007; 35: 5886-5897. (Pubitemid 47506303)
121. Chen PY, Weinmann L, Gaidatzis D, et al., Strand-specific 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity. RNA 2008; 14: 263-274. (Pubitemid 351171587)
122. Sano M, Sierant M, Miyagishi M, et al., Effect of asymmetric terminal structures of short RNA duplexes on the RNA interference activity and strand selection. Nucleic Acids Res 2008; 36: 5812-5821.
123. Sun X, Rogoff HA, Li CJ,. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nature Biotechnol 2008; 26: 1379-1382.
124. Ui-Tei K, Naito Y, Zenno S, et al., Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res 2008; 36: 2136-2151. (Pubitemid 351566989)
125. Chang CI, Yoo JW, Hong SW, et al., Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther 2009; 17: 725-732.
126. Lapierre J, Salomon W, Cardia J, et al., Potent and systematic RNAi mediated silencing with single oligonucleotide compounds. RNA 2011; 17: 1032-1037.
127. Lasham A, Herbert M, Coppieters 't Wallant N, et al., A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5′ RACE and a molecular beacon probe. Nucleic Acids Res 2010; 38: e19.
128. Alvarez R, Elbashir S, Borland T, et al., RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob Agents Chemother 2009; 53: 3952-3962.
129. Judge AD, Robbins M, Tavakoli I, et al., Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-673.
130. Davis ME, Zuckerman JE, Choi CHJ, et al., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010; 464: 1067-1070.
131. Bergan R, Hakim F, Schwartz GN, et al., Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996; 88: 731-741. (Pubitemid 26240406)
132. Spiller DG, Giles RV, Grzybowski J, et al., Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation. Blood 1998; 91: 4738-4746. (Pubitemid 28270324)
133. Li S, (ed). Electroporation Protocols: Preclinical and Clinical Gene Medicine (Methods in Molecular Biology, vol 423). Humana Press: New York, 2008.
134. Stein CA, Hansen JB, Lai J, et al., Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res 2010; 38: e3.
135. Zhang Y, Qu Z, Kim S, et al., Down-modulation of cancer targets using locked nucleic acid (LNA)-based antisense oligonucleotides without transfection. Gene Ther 18: 326-333.
136. Wang J, Lu Z, Wientjes MG, et al., Delivery of siRNA therapeutics: barriers and carriers. AAPS J 2010; 12: 492-503.
137. Juliano R, Alam MR, Dixit V, et al., Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 2008; 36: 4158-4171. (Pubitemid 351984831)
138. Koller E, Vincent TM, Chappell A, et al., Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res 2011; 39: 4795-4807.
139. Whitehead KA, Langer R, Anderson DG,. Knocking down barriers: advances in siRNA delivery. Nature Rev Drug Discov 2009; 8: 129-138.
140. Grimm D, Kay MA,. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117: 3633-3641. (Pubitemid 350224069)
141. De Paula D, Bentley MVLB, Mahato RI,. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 2007; 13: 431-456. (Pubitemid 46509424)
142. Akhtar S, Benter IF,. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 2007; 117: 3623-3632. (Pubitemid 350224068)
143. Li W, Szoka FC Jr,. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007; 24: 438-449. (Pubitemid 46295166)
144. Tseng YC, Mozumdar S, Huang L,. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009; 61: 721-731.
145. Eguchi A, Meade BR, Chang YC, et al., Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nature Biotechnol 2009; 27: 567-571.
146. Papahadjopoulos D, Allen TM, Gabizon A, et al., Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991; 88: 11460-11464. (Pubitemid 21916061)
147. Soutschek J, Akinc A, Bramlage B, et al., Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-178. (Pubitemid 39545841)
148. Semple SC, Akinc A, Chen J, et al., Rational design of cationic lipids for siRNA delivery. Nature Biotechnol 2010; 28: 172-176.
149. Dassie JP, Liu XY, Thomas GS, et al., Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nature Biotechnol 2009; 27: 839-849.
150. Song E, Zhu P, Lee S-K, et al., Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotechnol 2005; 23: 709-717. (Pubitemid 41716361)
151. Sato Y, Murase K, Kato J, et al., Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nature Biotechnol 2008; 26: 431-442. (Pubitemid 351501817)
152. Kim SS, Ye C, Kumar P, et al., Targeted delivery of siRNA to macrophages for anti-inflammatory treatment. Mol Ther 2010; 18: 993-1001.
153. Ferrari N, Bergeron D, Tedeschi A-L, et al., Characterization of antisense oligonucleotides comprising 2′-deoxy-2′-fluoro-beta- D -arabinonucleic acid (FANA): specificity, potency, and duration of activity. Ann N Y Acad Sci 2006; 1082: 91-102. (Pubitemid 44955454)
154. Stein D, Foster E, Huang SB, et al., A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev 1997; 7: 151-157. (Pubitemid 27323073)
155. Summerton JE,. Morpholino, siRNA, and S-DNA compared: impact of structure and mechanism of action on off-target effects and sequence specificity. Curr Top Med Chem 2007; 7: 651-660. (Pubitemid 46681848)
156. Gruenweller A, Wyszko E, Bieber B, et al., Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003; 31: 3185-3193. (Pubitemid 37441778)
157. Kretschmer-Kazemi Far R, Sczakiel G,. The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 2003; 31: 4417-4424. (Pubitemid 37441802)
158. Bennett CF, Swayze EE,. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol 2010; 50: 259-293.
159. Gagnon KT,. HD Therapeutics-CHDI Fifth Annual Conference (Meeting Report). IDrugs 2010; 13: 219-223.
160. Kunze D, Kraemer K, Fuessel, S,. Antisense oligonucleotides: insights from preclinical studies and clinical trials. In RNA Technologies and Their Applications, Erdmann V A, Barciszewski J, (eds). Springer-Verlag: Berlin, 2010; 285-303.
161. Haussecker D,. The business of RNAi therapeutics. Hum Gene Ther 2008; 19: 451-462. (Pubitemid 351748790)
162. Azad RF, Driver VB, Tanaka K, et al., Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993; 37: 1945-1954. (Pubitemid 23265557)
163. Grillone LR, Lanz R,. Fomivirsen. Drugs Today (Barc) 2001; 37: 245-255. (Pubitemid 32506283)
164. Bennett CF,. Pharmacological properties of 2′-O-methoxyethyl- modified oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications (2nd edn), Crooke ST, (ed). CRC Press: Boca Raton, 2008; 273-303.
165. Levin AA, Yu RZ, Geary RS,. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In Antisense Drug Technology: Principles, Strategies, and Applications (2nd edn), Crooke ST, (ed). CRC Press: Boca Raton, 2008; 183-215.
166. Raal FJ, Santos RD, Blom DJ, et al., Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 998-1006.
167. Crooke RM, Graham MJ, Lemonidis KM, et al., An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005; 46: 872-884.
168. Kling J,. Safety signal dampens reception for mipomersen antisense. Nature Biotechnol 2010; 28: 295-297.
169. Moulton HM, Moulton JD,. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010; 1798: 2296-2303.
170. Goyenvalle A, Davies KE,. Challenges to oligonucleotides-based
171. Wu B, Moulton HM, Iversen PL, et al., Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A 2008; 105: 14814-14819.
172. Yin H, Moulton HM, Betts C, et al., Functional rescue of dystrophin-deficient mdx mice by a chimeric peptide-PMO. Mol Ther 2010; 18: 1822-1829.
173. Yin H, Moulton HM, Betts C, et al., A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice. Hum Mol Genet 2009; 18: 4405-4414.
174. Yin H, Moulton HM, Seow Y, et al., Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008; 17: 3909-3918. (Pubitemid 352762853)
175. Jearawiriyapaisarn N, Moulton HM, Sazani P, et al., Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers. Cardiovasc Res 2010; 85: 444-453.
176. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al., Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624-1629.
177. Amantana A, Moulton HM, Cate ML, et al., Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 2007; 18: 1325-1331. (Pubitemid 47122656)
178. Elbashir SM, Lendeckel W, Tuschl T,. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200. (Pubitemid 32107664)
179. Corey DR,. RNAi learns from antisense. Nature Chem Biol 2007; 3: 8-11.
180. [No authors listed]. Silence is golden. Nature Biotechnol 2006; 24: 306-308.
181. Frederickson RM,. RNAi gets vote of confidence from big pharma. Mol Ther 2007; 15: 221-222. (Pubitemid 46111868)
182. Potera C,. Antisense-down, but not out. Nature Biotechnol 2007; 25: 497-499.
183. Schmidt C,. RNAi momentum fizzles as pharma shifts priorities. Nature Biotechnol 2011; 29: 93-94.
184. Zoubeidi A, Chi K, Gleave M,. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res 2010; 16: 1088-1093.
185. Agrawal S, Kandimalla ER,. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans 2007; 35: 1461-1467.
186. Harley CB,. Telomerase and cancer therapeutics. Nature Rev Cancer 2008; 8: 167-179. (Pubitemid 351305939)
187. Joseph I, Tressler R, Bassett E, et al., The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res 2010; 70: 9494-9504.